Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2011

01-01-2011 | Letter to the Editor

Same data sources, different pooled analysis result: the ongoing uncertainty in the subgroup analysis of RAD51 135G/C polymorphism and breast cancer risk

Authors: Pei-Hua Lu, Chen Li, Hong-Yi Zhou, Tong Wang, Chun-Qiang Chu, Wei Shen, Guo-Qing Tao

Published in: Breast Cancer Research and Treatment | Issue 1/2011

Login to get access

Excerpt

To the Editor, …
Literature
1.
Sun H, Bai J, Chen F, Jin Y, Yu Y, Jin L, Fu S (2010) RAD51 G135C polymorphism is associated with breast cancer susceptibility: a meta-analysis involving 22,399 subjects. Breast Cancer Res Treat [Epub ahead of print]
2.
Zhou GW, Hu J, Peng XD, Li Q (2010) RAD51 135G>C polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Res Treat [Epub ahead of print]
3.
Gao LB, Pan XM, Li LJ, Liang WB, Zhu Y, Zhang LS, Wei YG, Tang M, Zhang L (2010) RAD51 135G/C polymorphism and breast cancer risk: a meta-analysis from 21 studies. Breast Cancer Res Treat [Epub ahead of print]
4.
Hu R, Wei Y, Jiang WJ, Yao WX, Long QM, Zhang JH, Liang Y, Tang XL (2008) Association of polymorphisms of N372H in BRCA2 gene and 135G/C in RAD51 gene and breast cancers. Sichuan Da Xue Xue Bao Yi Xue Ban 39:973–975PubMed
5.
Lee KM, Choi JY, Kang C, Kang CP, Park SK, Cho H, Cho DY, Yoo KY, Noh DY, Ahn SH et al (2005) Genetic polymorphisms of selected DNA repair genes, estrogen and progesterone receptor status, and breast cancer risk. Clin Cancer Res 11:4620–4626CrossRefPubMed
6.
Chang TW, Wang SM, Guo YL, Tsai PC, Huang CJ, Huang W (2006) Glutathione S-transferase polymorphisms associated with risk of breast cancer in southern Taiwan. Breast 15:754–761CrossRefPubMed
7.
Yu KD, Yang C, Fan L, Chen AX, Shao ZM (2010) RAD51 135G>C does not modify breast cancer risk in non-BRCA1/2 mutation carriers: evidence from a meta-analysis of 12 studies. Breast Cancer Res Treat [Epub ahead of print]
8.
Wang Z, Dong H, Fu Y, Ding H (2010) RAD51 135G>C polymorphism contributes to breast cancer susceptibility: a meta-analysis involving 26,444 subjects. Breast Cancer Res Treat [Epub ahead of print]
Metadata
Title
Same data sources, different pooled analysis result: the ongoing uncertainty in the subgroup analysis of RAD51 135G/C polymorphism and breast cancer risk
Authors
Pei-Hua Lu
Chen Li
Hong-Yi Zhou
Tong Wang
Chun-Qiang Chu
Wei Shen
Guo-Qing Tao
Publication date
01-01-2011
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-1189-0

Other articles of this Issue 1/2011

Breast Cancer Research and Treatment 1/2011 Go to the issue

Preclinical study

Immunoconjugated gold nanoshell-mediated photothermal ablation of trastuzumab-resistant breast cancer cells

Epidemiology

Centrosome-related genes, genetic variation, and risk of breast cancer

Brief Report

Regional and seasonal influence in patient’s toxicity to adjuvant chemotherapy for early breast cancer

Brief Report

A recombination-based method to characterize human BRCA1 missense variants

Epidemiology

Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk

Preclinical study

Targeting trastuzumab-resistant breast cancer cells with a lentivirus engineered to bind antibodies that recognize HER-2
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits